Skip to main content
Medical information Clinical review pending

Cytogenetics

Lung Cancer Panel 3 EGFR ALK1 ROS1 MET

This genetic test identifies specific mutations (EGFR, ALK1, ROS1, MET) in lung cancer cells, helping guide personalized treatment decisions. Confirm with the laboratory before booking.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Tumor tissue sample (biopsy or surgical resection). Confirm specific requirements with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
No specific patient preparation is required. The sample is typically obtained via biopsy or surgery.
Test priceKSh 60,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Lung Cancer Panel 3 EGFR ALK1 ROS1 MET test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Diagnosis of non-small cell lung cancer (NSCLC)
  • ✓Guiding treatment decisions for NSCLC
  • ✓Identifying eligibility for targeted therapies
  • ✓Prognosis assessment in NSCLC
  • ✓Patients with symptoms suggestive of lung cancer
  • ✓Individuals with a history of smoking
02

In plain language

What this test helps you understand

Identifies specific genetic mutations in lung cancer tissue to guide personalized treatment strategies, including targeted therapies. Helps determine prognosis and potential response to specific drugs.
The Lung Cancer Panel 3 (EGFR, ALK1, ROS1, MET) test is a genetic analysis used in the diagnosis and management of lung cancer. It looks for specific changes, or mutations, in key genes within the tumor tissue. Identifying these mutations can help doctors understand the type of lung cancer and determine the most effective treatment strategies, including targeted therapies. This test is important for tailoring treatment plans to individual patients.

This test measures specific genetic mutations in tumor tissue, including: - EGFR: Epidermal Growth Factor Receptor - ALK1: Anaplastic Lymphoma Kinase - ROS1: ROS Proto-Oncogene 1 - MET: MET Proto-Oncogene, Receptor Tyrosine Kinase

This test is typically recommended for individuals diagnosed with non-small cell lung cancer (NSCLC) to help guide treatment decisions. It may also be considered for individuals with symptoms suggestive of lung cancer, a history of smoking, or a family history of the disease, as advised by a healthcare professional.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required. The sample is typically obtained via biopsy or surgery.
SampleTumor tissue sample (biopsy or surgical resection). Confirm specific requirements with the laboratory before booking.
MethodologyMolecular genetic testing, typically using Next Generation Sequencing (NGS) or similar techniques to detect mutations in the specified genes. Confirm with the laboratory before booking.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test analyzes specific genes and may not detect all possible mutations associated with lung cancer. Results should be interpreted in the context of the patient's overall clinical picture. A negative result does not rule out the presence of other mutations or treatment options. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

This test looks for specific genetic mutations in the EGFR, ALK1, ROS1, and MET genes within lung cancer cells.
Identifying these mutations helps doctors choose the most effective treatment plan, including targeted therapies, which can improve outcomes.
This test is typically recommended for individuals diagnosed with non-small cell lung cancer (NSCLC), as advised by their doctor.
A sample of the tumor tissue, usually obtained from a biopsy or surgery, is required for this test.
Confirm with the laboratory before booking.
Yes, a doctor’s prescription is required for this test, except in cases of surgery, pregnancy, or if you are planning to travel abroad.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp